title: [Retrospective analysis for 104 cases of early-stage Hodgkin's Lymphoma treated with different modality therapies].
abstract: This paper explored the curative effect of combined modality therapy and extended field radiotherapy for early-stage Hodgkin's Lymphoma. 104 cases of early-stage Hodgkin's Lymphoma from Jan 1987 to Dec 2010 in PLA Hospital 307 were retrospectively analyzed, including 76 cases in combined modality therapy group and 28 cases in extended field radiotherapy group, and the long-term efficacy and toxicity of two therapy modalities were evaluated. The results showed that the median survival time of 104 cases was 85.42 months, the complete remission rates of combined modality therapy and extended field radiotherapy groups were 72.4 and 71.4 respectively (P = 0.924); the overall response rates of combined modality therapy and extended field radiotherapy groups were 97.4 and 96.4 respectively (P = 0.779); the 5-year overall survival (OS) rates in the 2 groups were 89.5 and 89.1 respectively, and the 8-year OS rates of the 2 groups were 81.3 and 70.6. No statistical difference was found in above-mentioned 2 groups. Moreover, the 5-year progression free survival (PFS) rates of these 2 groups were 84.2 and 69.0 (P = 0.04), and 8-year PFS rates of these 2 groups were 80.0 and 55.5 (P = 0.04) respectively, the 5-year relapse rates of these 2 groups were 28.1 and 45.6 (P = 0.023) respectively. It is concluded that the combined modality therapy can raise the PFS rate and reduce the relapse rate as compared with extended field radiotherapy for early-stage Hodgkin's Lymphoma, but there is no difference in the overall survival rate between the 2 groups.
authors.affiliation: Chinese PLA Postgraduate Medical School, Beijing, China.
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Du
authors.forename: Xiu-Bin
authors.initials: XB
authors.lastname: Xiao
authors.forename: Hang
authors.initials: H
authors.lastname: Su
authors.forename: Yong
authors.initials: Y
authors.lastname: Da
authors.forename: Xin-Lin
authors.initials: XL
authors.lastname: Chen
authors.forename: Kai-Li
authors.initials: KL
authors.lastname: Zhong
authors.forename: Shi-Hua
authors.initials: SH
authors.lastname: Zhao
authors.forename: Yun
authors.initials: Y
authors.lastname: Lu
authors.forename: Shuang
authors.initials: S
authors.lastname: Wang
authors.forename: Wei-Jing
authors.initials: WJ
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult